Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

Ophthalmology

Volumn 121, Issue 11, 2014, Pages 2181-2192

  Ho, Allen C ^a   Busbee, Brandon G ^b   Regillo, Carl D ^a   Wieland, Mark R ^c   Van Everen, Sherri A ^d   Li, Zhengrong ^d   Rubio, Roman G ^d   Lai, Phillip ^d  

^a WILLS EYE HOSPITAL   (United States)

^b Tennessee Retina   (United States)

^c RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^d GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORNEA EDEMA; DIGESTIVE SYSTEM PERFORATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; FEMALE; FISTULA; GLAUCOMA; HEART INFARCTION; HERPES ZOSTER OPHTHALMICUS; HUMAN; HYPERTENSION; INTRAOCULAR PRESSURE; IRIDOCYCLITIS; IRITIS; LOADING DRUG DOSE; MACULAR DEGENERATION; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETINA ARTERY OCCLUSION; RETINA DETACHMENT; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA HEMORRHAGE; RETINA TEAR; RETINA VEIN OCCLUSION; SIDE EFFECT; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; VEIN THROMBOSIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA FOVEA; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MALE; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84908465944     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2014.05.009     Document Type: Article

References (26)

1. D.B. Rein, J.S. Wittenborn, and X. Zhang Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments Arch Ophthalmol 127 2009 533 540
2. T.Y. Wong, U. Chakravarthy, and R. Klein The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis Ophthalmology 115 2008 116 126
3. P.F. Lopez, B.D. Sippy, and H.M. Lambert Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes Invest Ophthalmol Vis Sci 37 1996 855 868
4. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
5. D.M. Brown, M. Michels, P.K. Kaiser ANCHOR Study Group Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study Ophthalmology 116 2009 57 65
6. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
7. B.G. Busbee, A.C. Ho, D.M. Brown HARBOR Study Group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
8. CATT Research Group Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
9. Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group, D.F. Martin, M.G. Maguire, and S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
10. IVAN Study Investigators, U. Chakravarthy, S.P. Harding, and C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 2012 1399 1411
11. J.S. Heier, D.M. Brown, V. Chong VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
12. U. Chakravarthy, S.P. Harding, C.A. Rogers IVAN Study Investigators Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 2013 1258 1267
13. A.W. Scott, and S.B. Bressler Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration Curr Opin Ophthalmol 24 2013 190 196
14. N. Ferrara, L. Damico, and N. Shams Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870
15. P.J. Rosenfeld, J.S. Heier, G. Hantsbarger, and N. Shams Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration Ophthalmology 113 2006 623 632
16. D.M. Brown, E. Chen, A. Mariani, J.C. Major Jr. SAVE Study Group Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration - primary end point Ophthalmology 120 2013 349 354
17. J.A. Haller Current anti-vascular endothelial growth factor dosing regimens: benefits and burden Ophthalmology 120 suppl 2013 S3 S7
18. D.R. Lally, A.T. Gerstenblith, and C.D. Regillo Preferred therapies for neovascular age-related macular degeneration Curr Opin Ophthalmol 23 2012 182 188
19. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
20. P. Abraham, H. Yue, and L. Wilson Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 2 Am J Ophthalmol 150 2010 315 324
21. D.S. Boyer, J.S. Heier, and D.M. Brown A phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
22. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
23. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58
24. C. Cukras, Y.D. Wang, and C.B. Meyerle Optical coherence tomography-based decision making in exudative age-related macular degeneration: comparison of time- vs spectral-domain devices Eye (Lond) 24 2010 775 783
25. Lucentis (ranibizumab injection) [package insert] 2014 Genentech, Inc. South San Francisco, CA Available at: www.gene.com/download/pdf/lucentis-prescribing.pdf Accessed April 2, 2014
26. U. Schmidt-Erfurth, P.K. Kaiser, and J.F. Korobelnik Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies Ophthalmolog 121 2014 193 201